NASDAQ · PODD
Healthcare · Medical - Devices
$140.60
Down-$0.95 (-0.67%)
Updated Sep 20, 2026, 5:30 PM
SID Score
4.7/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 19 trading sessions · Daily adjusted prices
PODD closed at $140.60 after 19 trading sessions, down 3.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $141.25 | $142.17 | $139.96 | $140.60 | 2.51M |
| Sep 17, 2026 | $140.38 | $141.80 | $138.51 | $141.55 | 1.2M |
| Sep 16, 2026 | $138.86 | $143.45 | $138.11 | $140.60 | 1.35M |
| Sep 15, 2026 | $137.59 | $140.28 | $136.16 | $139.24 | 1.5M |
| Sep 14, 2026 | $134.23 | $137.9801 | $131.61 | $137.80 | 2.34M |
| Sep 11, 2026 | $135.40 | $135.575 | $131.24 | $131.96 | 1.75M |
| Sep 10, 2026 | $136.74 | $138.66 | $134.11 | $134.68 | 1.87M |
| Sep 9, 2026 | $140.26 | $142.6919 | $137.25 | $137.92 | 2.06M |
| Sep 8, 2026 | $147.39 | $147.39 | $139.27 | $142.28 | 2.23M |
| Sep 4, 2026 | $149.32 | $150.56 | $145.42 | $147.48 | 1.06M |
| Sep 3, 2026 | $148.14 | $150.99 | $145.16 | $150.58 | 1.16M |
| Sep 2, 2026 | $148.00 | $151.50 | $147.21 | $148.14 | 1.11M |
| Sep 1, 2026 | $149.79 | $151.16 | $146.81 | $148.38 | 1.29M |
| Aug 31, 2026 | $142.93 | $149.68 | $142.005 | $148.66 | 6.64M |
| Aug 28, 2026 | $144.20 | $146.67 | $143.805 | $145.13 | 1.04M |
| Aug 27, 2026 | $142.96 | $144.60 | $140.98 | $143.41 | 1.34M |
| Aug 26, 2026 | $141.27 | $144.64 | $141.23 | $143.38 | 1.42M |
| Aug 25, 2026 | $145.28 | $146.095 | $141.78 | $143.05 | 1.93M |
| Aug 24, 2026 | $151.17 | $151.75 | $145.15 | $145.42 | 1.57M |
The latest Smart Investors Daily articles mentioning PODD.
PODD research
Company profile and research snapshot.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Leerink Partners | Market Perform | — |
| Aug 6, 2026 | Benchmark | Buy | — |
| Aug 6, 2026 | Bernstein | Outperform | — |
| Aug 6, 2026 | RBC Capital | Outperform | — |
| Aug 6, 2026 | TD Cowen | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 18, 2026
ACTON, Mass., September 18, 2026--Insulet Corporation (NASDAQ: PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum on Thursday, September 24, 2026, at 12:30 p.m. (Eastern Time).
Yahoo · Sep 17, 2026
Baron Capital, an investment management company, released its second-quarter 2026 investor letter for its “Baron SMID Cap ETF”. You can download the letter here. Baron SMID Cap ETF® (BCSM) gained 15.62% (NAV) in the second quarter, underperforming the Russell 2500 Growth Index’s 24.02% return. The trend towards “AI winners” continued, focusing on companies related to chips, […]
Yahoo · Sep 14, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.
Yahoo · Sep 14, 2026
A medical device giant now costs more than its faster-growing rivals, forcing investors to decide if its premium price tag is buying durable quality or just yesterday's story.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PODD.
